At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 242 enrolled
Drug / intervention
TAK-906 Maleate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine Receptor D2/D3 Antagonist, TAK-906 for the Treatment of Adult Subjects With Symptomatic Idiopathic or Diabetic Gastroparesis
In Brief
A Phase 2 clinical trial evaluating TAK-906 Maleate and Placebo for Diabetic Gastroparesis and Idiopathic Gastroparesis. Completed, enrolled 242 participants across 109 sites in 4 countries.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of treatment with 2 dose levels of TAK-906 in adult participants with gastroparesis compared with placebo during 12 weeks of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Gastroparesis, Idiopathic Gastroparesis
CountriesBelgium, Japan, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartOct 2018
Primary CompletionJun 2021
Study CompletionJul 2021
TodayJul 2026
First PostedJun 1, 2018
Enrollment StartOct 14, 2018
Primary CompletionJun 14, 2021
Study CompletionJul 15, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 8.1 years ago
Interventions
TAK-906 Maleatedrug
TAK-906 maleate capsules.
Placebodrug
TAK-906 maleate placebo-matching capsules.